Prognostic Biomarkers in Active Surveillance: Parsing Risk in Early Stage Prostate Cancer
Abstract
While a majority of prostate cancers (PCa) remain clinically insignificant, some have the potential to metastasize and become lethal and therefore merit intervention. Thus, identification of men most at risk and most likely to benefit from therapy is a major clinical and public health challenge. Recent evidence suggests that the clinical-pathologic criteria used to assess eligibility for active surveillance and to define progression requiring intervention do not capture molecular changes that may more accurately predict progression of tumors from indolent to aggressive.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 2018
- Accession Number
- AD1060289
Entities
People
- David J Einstein
Organizations
- Beth Israel Deaconess Medical Center